CS
ATNM icon

Credit Suisse’s Actinium Pharmaceuticals ATNM Stock Holding History

Credit Suisse’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$11 – 3294
2022
Q4 		$11 Hold
1
– – ﹤0.01% 3722
2022
Q3 		$0 Hold
1
– – ﹤0.01% 4036
2022
Q2 		$0 Buy
+1
New +$6 ﹤0.01% 3918
2018
Q3 		– Sell
-43,674
Closed -$839K – 3776
2018
Q2 		$839K Buy
43,674
+16,667
+62% +$211K ﹤0.01% 3141
2018
Q1 		$296K Hold
27,007
– – ﹤0.01% 3574
2017
Q4 		$538K Buy
27,007
+2,007
+8% +$40.4K ﹤0.01% 3397
2017
Q3 		$431K Buy
+25,000
New +$549K ﹤0.01% 3572

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Credit Suisse's ATNM Position: Q1 2023 in Review

Credit Suisse sold out of Actinium Pharmaceuticals (ATNM) in Q1 2023, closing a stake of 1 share — an estimated $11 sold.

Credit Suisse first reported a position in ATNM in Q3 2017 and held it in 7 quarters. The position peaked at $839K in Q2 2018. 64 funds tracked by Wall St. Rank hold ATNM as of Q1 2023.

  • Credit Suisse reported no remaining Actinium Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 1 Actinium Pharmaceuticals share in Q1 2023, an estimated $11.
  • Credit Suisse first reported a position in Actinium Pharmaceuticals in Q3 2017 and held it in 7 quarters.
  • Credit Suisse's Actinium Pharmaceuticals position peaked at $839K in Q2 2018.
  • 64 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.